Summary
Sixty-eight patients with “advanced ovarian carcinoma” were entered into an ongoing phase-II trial for remission induction with cis-platinum (DDP) 80 mg/m2 i.v. on day 1 followed by forced saline diuresis, melphalan (L-PAM) 12 mg/m2 i.v. on day 2 and hexamethylamine (HMM) 130 mg/m2 p.o. x 14 days from days 8–21 in six monthly cycles following operative resection and/or staging. Fifty-one patients were evaluable for response, ten had not completed six courses and could not be assessed, two patients died early (one probably of toxicity), and five patients refused treatment and follow-up. Thirty-Two patients had serous, endometrioid or undifferentiated carcinomas of the ovary. Of these, 11 (35%) achieved a pathologically proven complete remission (CR), five (16%) were NED after second-look (residual disease in ovary or removed omentum with all other biopsies and cytology washings negative), eight (32%) achieved a partial remission (PR), and three (12%) had progressive disease. None of the seven patients with clear-cell carcinoma and none of the three patients with mixed Mullerian tumor of the ovary responded. Six of nine patients with tumors of uncertain origin or proven metastasis to ovary did not respond to treatment. These preliminary results indicate that advanced ovarian carcinomas form a heterogeneous group of recognizable neoplastic diseases with striking variation in response to treatment.
Similar content being viewed by others
References
Goldhirsch A, Greiner R, Davis B Chemotherapie followed by whole-abdominal radiation for ovarian cancer. Alberts DS, Surwit EA (eds) Gyn Oncology II (to be published)
Neijt JP, Ten Bokkel Huiniuk WM, van den Burg MEL, van Oosterom AT, Vriesendorp R, Boven E, Kooyman CD, van Honurelingen JC, Pinedo HM (1983) Combination chemotherapy with hexa-CAF and CHAP-5 in advanced ovarian carcinoma: A randomized study of the Netherlands joint study group for ovarian cancer. Proc ASCO 2:148
Dembo AJ, Brown TC, Bush RS, Sturgeon JFG (1982) Prognostic significance of pathology subtype and differentiation in epithelial carcinoma of the ovary. Proc ASCO Abstract C406
Greiner R, Goldhirsch A, Dreher E, Davis B, Locher G, Payer T, Neuenschwander H, Joss R, Brunner K, Veraguth P Wholeabdominal radiation in patients with advanced ovarian carcinoma after surgery, chemotherapy and second-look laparotomy. Eur J Cancer Clin Oncol (in press)
Serov SF, Scully RE, Sobin LH (1973) International histological classification of tumors, No. 9. Histological Typing of Ovarian Tumors. Geneva, World Health Organization
Aure JC, Høeg K, Kolstad P (1971) Clinical and histological studies of ovarian carcinoma: long term follow-up of 900 cases. Obstet Gynecol 37:1
Kottmeier HL (1979) Annual report on the results of treatment in gynecological cancer vol. 17. Statement of results obtained in 1969 to 1972. FIGO. Stockholm
Young RC, Hubbard SP, DeVita VT (1974) The chemotherapy of ovarian carcinoma. Cancer Treat Rev 1:99
Smith JP, Rutledge F, Wharton JT (1972) Chemotherapy of ovarian cancer: new approaches to treatment. Cancer 30:1565
Omura G (1981) Are all stage III cancers of the ovary really cancers of the ovary? Cancer Clin Trials 4:219
Nissenblatt MJ (1981) The CUP syndrome (carcinoma of unknown primary). Cancer Treat Rev 8:211
Julian C, Woodruff JD (1969) The role of chemotherapy in treatment of primary ovarian malignancy. Obstet Gynecol Surg 24:1307
Ozols RF, Garvin AJ, Cost J (1975) Histological grade in advanced ovarian cancer. Cancer Treat Rep 63:255
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Davis, B.W., Goldhirsch, A., Locher, G.W. et al. Pathologic data of prognostic significance for remission induction in advanced ovarian carcinoma. J Cancer Res Clin Oncol 107, 106–110 (1984). https://doi.org/10.1007/BF00399381
Issue Date:
DOI: https://doi.org/10.1007/BF00399381